Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study

Grace Qian, Xiaosong Wang, Naomi J. Patel, Yumeko Kawano, Xiaoqing Fu, Claire Cook, Kathleen M.m. Vanni, Emily Kowalski, Emily Banasiak, Katarina J Bade, Shruthi Srivatsan, Zachary K Williams, Derrick J. Todd, Michael E. Weinblatt, Zachary S. Wallace, Jeffrey A. Sparks

TL;DR

This retrospective cohort study demonstrates that outpatient treatments (like Paxlovid and monoclonal antibodies) reduced the risk of hospitalization or death by 88% in patients with systemic autoimmune rheumatic diseases (SARDs). Despite high vaccination rates, at least 8% of these patients experienced "COVID-19 rebound" after oral antiviral treatment, highlighting a need for vigilant follow-up in vulnerable populations.

What Problem Does This Paper Address?

Patients with systemic autoimmune rheumatic diseases (SARDs)—such as rheumatoid arthritis or lupus—face a double-edged sword during the COVID-19 pandemic. Their underlying conditions and the immunosuppressive medications they take to manage them can impair vaccine efficacy and increase the risk of severe infection.

While clinical trials for oral antivirals like nirmatrelvir/ritonavir (Paxlovid) and molnupiravir showed great promise, those trials were largely conducted in unvaccinated general populations before the emergence of the Omicron variant. There has been a significant data gap regarding how these treatments perform in the "real world" for high-risk, highly vaccinated SARD patients. Furthermore, the phenomenon of "COVID-19 rebound"—where symptoms or positive tests return after a period of recovery—has been reported anecdotally, but its prevalence in the SARD population remained unquantified.

Methods

The researchers conducted a retrospective cohort study using data from the Mass General Brigham (MGB) healthcare system in Boston. They analyzed 704 SARD patients who contracted COVID-19 between January and May 2022 (the height of the Omicron wave).

Key methodological features included:

  • Case Identification: A combination of electronic health record (EHR) queries for positive PCR/antigen tests and a validated algorithm to identify SARD patients (requiring specific diagnosis codes plus immunomodulator prescriptions).
  • Manual Review: Unlike many large-scale database studies, the authors performed manual medical record reviews to confirm outpatient treatment status and identify documented cases of rebound.
  • Statistical Rigor: They used multivariable logistic regression to calculate adjusted odds ratios (aOR), controlling for potential confounders like age, the Charlson Comorbidity Index (CCI), kidney function (eGFR), and race.

Datasets

The study utilized the MGB Research Patient Data Registry, a massive repository pulling from 14 hospitals and numerous outpatient centers in the greater Boston area. While no new public benchmark was introduced, the study relied on a previously validated administrative data algorithm for SARD identification that boasts a 90% positive predictive value.

Key Insights and Ideas

  • The Power of Outpatient Care: Even in a population where 96% were vaccinated, outpatient treatment provided a massive additional layer of protection. The 88% reduction in severe outcomes suggests that vaccination alone isn't the ceiling for protection in immunocompromised groups.
  • Treatment Trends: The study captured a shift in clinical practice; treatment rates rose from 35% at the start of the study period to 65% by the end, reflecting growing clinician confidence and drug availability.
  • The Rebound Reality: An 8% rebound rate is significant. Because the study required formal documentation in the EHR (a negative test followed by a new positive and symptom recurrence), this is likely a "floor" estimate. The actual rate of rebound in the community is probably higher.
  • Equivalency of Options: In secondary analyses, both Paxlovid and monoclonal antibodies were highly effective, with no statistically significant difference between them, offering clinicians flexibility based on patient contraindications (like kidney function).

Key Results

  • Primary Outcome: Only 2.1% of treated patients were hospitalized or died, compared to 17.6% of untreated patients.
  • Risk Reduction: The adjusted odds ratio (aOR) for any outpatient treatment was 0.12 (95% CI 0.05 to 0.25).
  • Specific Treatments:
    • Nirmatrelvir/ritonavir (Paxlovid) aOR: 0.08
    • Monoclonal antibodies aOR: 0.20
  • Rebound: 25 out of 318 patients (8%) who received oral antivirals experienced a documented rebound. Reassuringly, none of the rebound cases in this study resulted in subsequent hospitalization.

Limitations and Future Work

The authors acknowledge several limitations:

  1. Generalizability: The study was conducted in a single geographic area with a very high vaccination rate. Results might differ in regions with lower vaccine uptake.
  2. Selection Bias: Patients who seek testing and treatment might differ fundamentally from those who manage the illness at home with rapid tests, potentially biasing results.
  3. Rebound Definition: The strict requirement for EHR documentation means many cases of rebound were likely missed.
  4. Unmeasured Confounding: Factors like social determinants of health or specific contraindications to certain drugs could not be fully accounted for.

Future Work: The authors call for prospective studies to better ascertain the true prevalence of rebound and investigate whether longer treatment courses might be necessary for the most severely immunosuppressed patients to ensure complete viral clearance.

Summary updated

Abstract

These results should encourage clinicians to prescribe and SARD patients to seek prompt outpatient COVID-19 treatment.This research provides an early estimate of the prevalence of COVID-19 rebound after oral outpatient treatment to quantify this risk to clinicians and SARD patients and encourage future research.
BibTeX
@inproceedings{qian2023outcomes,
  author = {Grace Qian and Xiaosong Wang and Naomi J. Patel and Yumeko Kawano and Xiaoqing Fu and Claire Cook and Kathleen M.M. Vanni and Emily Kowalski and Emily Banasiak and Katarina J Bade and Shruthi Srivatsan and Zachary K Williams and Derrick J. Todd and Michael E. Weinblatt and Zachary S. Wallace and Jeffrey A. Sparks},
  title = {{Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study}},
  booktitle = {The Lancet Rheumatology},
  year = {2023},
  doi = {10.1016/s2665-9913(23)00006-1},
}
Figure